To study the functional role of individual ␣ 1 -adrenergic (AR) subtypes in blood pressure (BP) regulation, we used mice lacking the ␣ 1B -AR and/or ␣ 1D -AR with the same genetic background and further studied their hemodynamic and vasoconstrictive responses. Both the ␣ 1D -AR knockout and ␣ 1B -/ ␣ 1D -AR double knockout mice, but not the ␣ 1B -AR knockout mice, had significantly (p Ͻ 0.05) lower levels of basal systolic and mean arterial BP than wild-type mice in nonanesthetized condition, and they showed no significant change in heart rate or in cardiac function, as assessed by echocardiogram. All mutants showed a significantly (p Ͻ 0.05) reduced catecholamine-induced pressor and vasoconstriction responses. It is noteworthy that the infusion of norepinephrine did not elicit any pressor response at all in ␣ 1B -/␣ 1D -AR double knockout mice. In an attempt to further examine ␣ 1 -AR subtype, which is involved in the genesis or maintenance of hypertension, BP after salt loading was monitored by tail-cuff readings and confirmed at the endpoint by direct intra-arterial recording. After salt loading, ␣ 1B -AR knockout mice developed a comparable level of hypertension to wild-type mice, whereas mice lacking ␣ 1D -AR had significantly (p Ͻ 0.05) attenuated BP and lower levels of circulating catecholamines. Our data indicated that ␣ 1B -and ␣ 1D -AR subtypes participate cooperatively in BP regulation; however, the deletion of the functional ␣ 1D -AR, not ␣ 1B -AR, leads to an antihypertensive effect. The study shows differential contributions of ␣ 1B -and ␣ 1D -ARs in BP regulation.Catecholamines released from sympathetic nerve terminals cause vascular smooth muscle contraction primarily by activating ␣ 1 -adrenergic receptors (␣ 1 -ARs) in arteries (Hoffman, 2001). Thus, blockade of ␣ 1 -AR leads to a fall in peripheral vascular resistance. Because of their consistent effect in lowering systemic blood pressure (BP), ␣ 1 -AR blockers have been widely used as an antihypertensive drug. However, a large clinical trial unexpectedly disclosed that doxazosin, a nonselective ␣ 1 -AR antagonist, was associated with an increased incidence of heart failure (ALLHAT Collaborative Research Group, 2000). This raised a serious concern about the long-term use of ␣ 1 -AR antagonists in the treatment of hypertension (HT) (ALLHAT Collaborative Research Group, 2000). On the other hand, clinical efficacy of a subtypeselective inhibition of ␣ 1 -AR has not been fully determined.This work was supported in part by research grants from the Scientific Fund of the Ministry of Education, Science, and Culture of Japan, the Japan Health Science Foundation and Ministry of Human Health and Welfare.C.H. and T.K. contributed equally to this work. Article, publication date, and citation information can be found at http://molpharm.aspetjournals.org. doi:10.1124/mol.104.007500.
ABBREVIATIONS: ␣